|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
It was found that Hsp90 inhibition in neuroblastoma cell lines resulted in significant growth suppression, a decrease in MYCN and MYC expression, and an increase in the expression of p53.
|
21109931 |
2011 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We identified a genetic signature characterized by a subset of MYCN/MYC and E2F targets, including Skp2, encoding the F-box protein of the SCF(Skp2) E3-ligase, to be highly expressed in high-risk neuroblastomas independent of amplified MYCN.
|
17652624 |
2007 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells.
|
10625678 |
2000 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
For in vivo validation we selected CSNK1e, a kinase whose expression correlated with MYCN amplification in neuroblastoma (an established MYC-driven cancer).
|
22623531 |
2012 |
|
Neuroblastoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Translocation (e.g., c-myc in Burkitt's lymphoma), or amplification (e.g., N-myc in neuroblastoma) of myc genes has been causally linked to tumor formation.
|
12769686 |
2003 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Specific inhibition of hyperactive rRNA synthesis and protein translation was shown to be an effective way to suppress MYC/MYCN protein expression and neuroblastoma growth.
|
29464082 |
2018 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study implicates the role of BORIS/CTCFL in maintenance of stemness and in transition from mesenchymal to epithelial state in MYC amplified neuroblastoma IMR-32 cells.
|
28104398 |
2017 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
N-myc is a DNA sequence which shares limited homology to the proto-oncogene c-myc and has been found to be amplified in both primary tissue and cell lines from neuroblastoma, a childhood tumour of neuroectodermal origin.
|
3855502 |
1985 |
|
Neuroblastoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
MYC has been shown to associate with DNA methyltransferases, thereby inducing transcriptional repression of target genes, which suggested that MYCN might play a similar mechanistic role in the hypermethylation of tumor suppressor genes in neuroblastoma.
|
23280764 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conclusions MYC-amplified neuroblastomas are extremely rare and seem to present with distinct clinicopathological features.
|
29426276 |
2019 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data implicate tissue-specific enhancers in defining often highly tumor-specific 'MYC target gene signatures' and identify disruption of the MYCN enhancer regulatory axis as a promising therapeutic strategy in neuroblastoma.
|
29379199 |
2018 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunostaining for MYCN and MYC protein was performed on 357 undifferentiated/poorly differentiated neuroblastomas.
|
26035700 |
2015 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN have overlapping functions.
|
19946337 |
2010 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest that epigenetic and posttranslational inhibition of MYC/MYCN-driven pathways may have significant clinical efficacy against neuroblastoma.
|
30153557 |
2018 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The more complex expression pattern found for the Myc targets in neuroblastomas suggests that genes that were identified originally as targets for c-Myc regulation may be regulated by N-Myc, but other cell specific factors are also needed for transcription of the target genes.
|
9674700 |
1998 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The involvement of the MYC-MAX-MXD1 network in the development and progression of neural crest cell tumors is further supported by the lack of functional MAX in rat PCC (PC12) cells and by the amplification of MYCN in neuroblastoma and suggests that loss of MAX function is correlated with metastatic potential.
|
21685915 |
2011 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analysis of human neuroblastoma tumor specimens revealed that MYC up-regulation correlates with markers of TAM infiltration.
|
29207662 |
2017 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Relationship between bcl-2 and myc gene expression in human neuroblastoma.
|
7767905 |
1995 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis.
|
26373717 |
2016 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
|
8761367 |
1996 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Of note, expressions of MCT1 and MCT2 were each significantly elevated in MYCN-amplified neuroblastomas and C-MYC-overexpressing lymphomas than in tumors without MYC overexpression, correlating with poor prognosis and unfavorable patient survival.
|
26434591 |
2016 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we found miR-1303 was upregulated in NB cells and tissues, miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect. mechanism analysis suggested glycogen synthase kinase 3 beta (GSK3β) and secreted frizzled-related protein 1 (SFRP1) were the target of miR-1303, luciferase assay revealed miR-1303 directly bound to the 3'UTR of GSK3β and SFRP1. miR-1303 increased expression of MYC and CyclinD1, and decreased the expression of p21 and p27, and further demonstrated miR-1303 promotes NB proliferation.
|
27434867 |
2016 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although MYC translocations define Burkitt lymphoma and MYC protein expression is a poor prognostic factor in undifferentiated neuroblastomas, the distribution of MYC protein (c-MYC) across other pediatric small round blue cell tumors (SRBCT) has not been well characterized.
|
28521631 |
2017 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The xenografts established from the NB iCSCs shared two common features: the LCN phenotype and high-level MYC/MYCN expression.
|
23479628 |
2013 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification.
|
25475555 |
2015 |